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Abstract   Infectious diseases are becoming a major menace to the state of health 4 
worldwide, with difficulties in effective treatment especially of nosocomial infec-5 
tions caused by Gram negative bacteria being increasingly reported. Inadequate 6 
permeation of anti-infectives into or across the Gram negative bacterial cell enve-7 
lope, due to its intrinsic barrier function as well as barrier enhancement mediated 8 
by resistance mechanisms, can be identified as one of the major reasons for insuf-9 
ficient therapeutic effects. Several in vitro, in silico and in cellulo models are cur-10 
rently employed to increase knowledge of anti-infective transport processes into or 11 
across the bacterial cell envelope, however all such models exhibit drawbacks or 12 
have limitations with respect to the information they are able to provide. Thus, 13 
new approaches which allow for more comprehensive characterization of anti-14 
infective permeation processes (and as such, would be usable as screening meth-15 
ods in early drug discovery and development) are desperately needed. Further-16 
more, delivery methods or technologies capable of enhancing anti-infective per-17 
meation into or across the bacterial cell envelope are required. In this respect, 18 
particle-based carrier systems have already been shown to provide the opportunity 19 
to overcome compound related difficulties and allow for targeted delivery. In ad-20 
dition, formulations combining efflux pump inhibitors or antimicrobial peptides 21 
with anti-infectives show promise in the restoration of antibiotic activity in re-22 
sistant bacterial strains. Despite considerable progress in this field however, the 23 
design of carriers to specifically enhance transport across the bacterial envelope or 24 
to target difficult to treat (e.g. intracellular) infections remains an urgently needed 25 
area of improvement. What follows is a summary and evaluation of the state of the 26 
art of both bacterial permeation models and advanced anti-infective formulation 27 
strategies, together with an outlook for future directions in these fields.    28 
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1. Introduction 76 
The effective treatment of infectious diseases by means of anti-infective drug 77 
therapies is currently associated with a significant and increasing level of difficul-78 
ty. The incidence of nosocomial infections caused in particular by pathogenic bac-79 
teria is an indicator of this problem. In Germany alone 400 000 – 600 000 hospi-80 
tal-acquired, bacterial infections occur per year; 7500 – 15 000 of such cases are 81 
in fact lethal (Akademie der Wissenschaften and Deutsche Akademie der 82 
Naturforscher 2013). These statistics are mainly due to the increasing incidence of 83 
bacterial resistance to drug therapy, leading to a lack of sufficiently active anti-84 
infective treatment options. Gram negative bacteria are particularly problematic in 85 
this respect: as an example, carbapenem-resistant-Enterobacteriaceae (CRE, for 86 
abbreviations see Table 1) are capable of evading the action of almost all current-87 
ly-available antibiotics. This dire trend leads to the occurrence of nearly un-88 
treatable infections, with only two ‘last resort’ antibiotics available (tigecycline 89 
and colistin) - neither of which are effective in every patient (McKenna 2013). We 90 
are therefore faced with a major global challenge with respect to the successful 91 
treatment of Gram negative bacterial infections (Wellington et al. 2013).  92 
 93 
While resistance to anti-infective drug therapies is without doubt the primary 94 
threat to effective infectious disease treatment, the evolution of resistance is com-95 
pounded by a number of additional factors. Firstly, the successful delivery of anti-96 
infectives to their site of action constitutes a challenging and complicated task, 97 
even in the case of a wild type bacterium. This is due to the fact that the bacterial 98 
cell envelope, especially that of Gram negative bacteria, works intrinsically as a 99 
complex and significant biological barrier to the effective delivery of anti-100 
infective compounds and formulations (see section 2.1, Nelson et al. 2009). The 101 
occurrence of several resistance mechanisms such as up-regulation of efflux pump 102 
expression, down-regulation or alteration of the expression of transport and chan-103 
nel-forming proteins (e.g. porins) and the production of enzymes (e.g. ß-104 
lactamase) within this envelope structure therefore acts to compound an already 105 
existing problem for anti-infectives which must penetrate into or entirely through 106 
the bacterial envelope in order to reach their site of action (Dever and Dermody 107 
1991). As a further factor for consideration, from the so-called golden age of anti-108 
biotic discovery - lasting from the 1950s to the 1960s (Fischbach and Walsh 2009) 109 
- until the introduction of the oxazolidinones in 2000, no new anti-infective class 110 
was able to successfully reach the market. This low flow within the antibiotic de-111 
velopment pipeline continues today, meaning that the diminishing pool of effec-112 
tive therapies is not being replenished by newly-emerging treatment options.  113 
The above described factors contributing towards the problematic nature of effec-114 
tive infection treatment can collectively be regarded as symptoms of a bacterial 115 
bioavailability problem. Such a bioavailability issue draws attention to two signif-116 
icant necessities in the area of anti-infective research. 117 
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The first is the desperate need for new models and strategies to better investigate 118 
and characterize the trafficking of anti-infectives into or across the bacterial cell 119 
envelope, in order to increase collective knowledge of the envelope as a barrier 120 
which needs to be overcome. As a second need, novel anti-infective candidates 121 
with new modes of action are required, as are new delivery strategies which ena-122 
ble effective penetration into or across the Gram negative bacterial cell envelope. 123 
The current document will attempt to address aspects of both research needs, out-124 
lining the state of the art in each area as well as potential or actual future research 125 
directions. Specific emphasis will continue to be given to Gram negative bacteria 126 
as particularly problematic pathogens.  127 
 128 
Table 1. Abbreviations, in alphabetical order. 129 
AMPs Antimicrobial peptides 
CRE Carbapenem-resistant Enterobacteriacae 
DUV Deep ultraviolet 
EPIs Efflux pump inhibitors 
IM Inner membrane 
LB Langmuir-Blodgett 
LS Langmuir-Schaefer 
LPS Lipopolysaccharides 
MD Molecular dynamics 
MIC Minimal inhibitory concentration 
MRSA Methicillin-resistant Staphylococcus aureus  
OD Optical density 
OM Outer membrane 
OMPs Outer membrane proteins 
PaßN Phenylalanin arginyl ß-naphtylamine 
PC Phosphatidylcholine 
PE Phosphatidylethanolamine 
PG Phosphatidylglycerol 
PL Phospholipid 
PS Periplasmic space 
QSARs Quantitative structure-activity relationships 
QSI Quorum sensing inhibitor 
RND Resistance-nodulation-cell division 
SLBs Supported lipid bilayers 
SLNs Solid lipid nanoparticles 
 130 
 131 
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2. The Gram Negative Bacterial Cell Envelope as a 132 
Bioavailability Barrier to Anti-Infectives 133 
As already mentioned, the intrinsic structure of the Gram negative bacterial cell 134 
envelope presents a significant barrier to the successful delivery of anti-infectives. 135 
Therefore a brief overview of the major structural components of the cell enve-136 
lope, including details of envelope modifications responsible for the occurrence 137 
and evolution of resistance, is first given here.  138 
 139 
 140 
2.1 The Intrinsic Bacterial Barrier 141 
 142 
The Gram negative bacterial cell envelope can be divided into three major parts, 143 
each of which constitutes a significant obstacle to anti-infective penetration (Fig-144 
ure 1). Starting from the bacterial cytoplasm and proceeding outwards, the inner 145 
membrane (IM) represents the first layer of the envelope barrier. It consists of a 146 
phospholipid (PL) bilayer mainly composed of phosphatidylethanolamine (PE), 147 
phosphatidylglycerol (PG) and cardiolipin, with incorporated transmembrane pro-148 
teins and lipoproteins. The periplasmic space (PS) with the peptidoglycan cell wall 149 
constitutes the second layer. Peptidoglycan, a polymer of repeating disaccharides, 150 
is responsible for the maintenance of cell shape and structure. The surrounding ar-151 
ea is a highly viscous, aqueous compartment, densely packed with proteins 152 
(Mullineaux et al. 2006). Furthermore defense mechanisms including enzymes 153 
(e.g. ß-lactamase) are also located within this space. The outer membrane (OM) 154 
forms the third envelope sub-structure. The membrane itself is asymmetric in na-155 
ture, being subdivided into a PL- (mainly PE) containing inner leaflet, and an out-156 
er leaflet mainly consisting of lipopolysaccharide (LPS). LPS in turn is composed 157 
of the so-called Lipid A, a phosphorylated glucosamine with six to seven acyl 158 
chains which anchors LPS to the inner leaflet of the OM; a core oligosaccharide; 159 
and the outermost portion of the molecule, the O-antigen. LPS acyl chains are 160 
mainly saturated, which confers a gel-like structure on the molecule. Association 161 
of gel-like LPS molecules within the outer leaflet is additionally strengthened by 162 
the presence of divalent cations being present in the surrounding medium, which 163 
neutralize the negative charge of LPS phosphate groups. This further contributes 164 
to the formation of a viscous structure which limits the permeation of hydrophobic 165 
compounds, including many anti-infectives and detergents. The OM also incorpo-166 
rates outer membrane proteins (OMPs) such as the porins (e.g. OmpF), which 167 
span the entire OM. Porins allow for and control the passive diffusion of hydro-168 
philic compounds, for example ß-lactam antibiotics, with a size limit for such 169 
permeation of approximately 700 Dalton (Silhavy et al. 2010). The combination of 170 
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LPS and porins is therefore responsible for the strong permeability limiting prop-171 
erties of the OM, which acts to restrict the permeation of hydrophobic as well as 172 
hydrophilic compounds. 173 
 174 
In addition, efflux transporters, most commonly belonging to the resistance-175 
nodulation-cell division (RND) superfamily, feature prominently within the cell 176 
envelope. Sub-structures of these transporters are present in each of the three ma-177 
jor envelope subsections (for example AcrB-AcrA-TolC and MexB-MexA-OprM 178 
where subunits are located in the IM-PS-OM) meaning that the pump as a whole 179 
spans the entire envelope structure. Such efflux pumps are responsible for the ac-180 
tive excretion of compounds (e.g. anti-infectives) in an energy-dependent manner 181 
(Kumar and Schweizer 2005). 182 
 183 
 184 
  185 
 186 
 187 
 188 
 189 
 190 
 191 
 192 
 193 
 194 
 195 
Fig. 1. Transmission electron microscopy image of the cell envelope of Legionella dumoffii 196 
(A, adapted from Palusinska-Szysz et al. 2012) and schematic overview of the Gram nega-197 
tive bacterial cell envelope, highlighting the most important structural components (B): the 198 
inner membrane (IM) incorporating transmembrane and lipoproteins, the periplasmic 199 
space (PS) housing the peptidoglycan cell wall, and the asymmetric outer membrane (OM) 200 
with its lipopolysaccharide (LPS) outer leaflet and porins. The general structure of an ef-201 
flux transporter is also shown.   202 
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2.2 The Role of the Envelope in Mediating Resistance Mechanisms  203 
In principle we can differentiate between three major, antimicrobial resistance 204 
strategies of bacteria: i) degradation of anti-infective compounds by bacterial en-205 
zymes, ii) protection of anti-infective targets by e.g. structural or expression modi-206 
fication, and, of most relevance to the current document, iii) alteration of the cell 207 
envelope barrier function (Davin-Regli et al. 2008), which will here be further de-208 
scribed. Modifications to barrier properties result in an increased efflux in combi-209 
nation with a reduced uptake of anti-infectives, leading to inadequate intracellular 210 
anti-infective levels. The increased efflux of anti-infectives occurs due to an over-211 
expression of efflux pumps (as mentioned above), which have a broad range of ac-212 
tion and as such, are able to mediate resistance to a variety of anti-infective classes 213 
(Tenover 2006). Resistance in the context of reduced uptake arises due to bacterial 214 
modification of OMP copy numbers or conformation, and/or alterations in LPS 215 
structure. The expression of OMPs, in particular porins, can be down-regulated 216 
within the OM structure, or can alternatively be completely abrogated (Nikaido 217 
and Rosenberg 1981). The latter case is for example known from Escherichia coli 218 
isolates, which are resistant against cefoxitin due to an absence of the major OmpF 219 
porin channel (Tenover 2006). Furthermore, bacteria can modify the structure of 220 
their porins as a strategy to prevent anti-infective entry. Such structural modifica-221 
tion can for example consist of a narrowing of the porin channel, which decreases 222 
the permeation of larger, hydrophilic compounds (De et al. 2001). The structure of 223 
LPS molecules can additionally be altered, in order to facilitate an increase in the 224 
barrier properties of the OM. The most effective mechanism by which LPS altera-225 
tion leads to increased barrier function is via a reduction of negative net charge, 226 
leading to a reduced permeation of cationic anti-infectives (Kumar and Schweizer 227 
2005).  228 
2.3 Implications for Anti-Infective Drug Delivery  229 
Clearly, the unique structure of the Gram negative bacterial cell envelope, together 230 
with the ability of bacteria to alter the structure and resulting functional activity of 231 
various envelope components, creates a considerable hurdle to the cellular perme-232 
ation of anti-infectives. The development and application of models in order to fa-233 
cilitate an increased understanding of envelope permeation processes as well as 234 
the investigation of new anti-infective delivery approaches are therefore intro-235 
duced and discussed below, as two research strategies required in order to address 236 
the issue of inadequate anti-infective permeation.  237 
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3. Strategies to Combat Intrinsic Difficulties/Bacterial 238 
Resistance Mechanisms Related to Anti-Infective Transport 239 
3.1 Models for Characterization of Drug Transport Across the 240 
Bacterial Cell Envelope 241 
As detailed above, the Gram negative bacterial cell envelope works as an effective 242 
biological barrier to the successful delivery of anti-infectives to their target site. 243 
The fundamental existing barrier properties of the envelope are also able to be fur-244 
ther increased through the up-regulation of resistance mechanisms. Therefore, in 245 
addition to well-established and commonly used efficacy testing approaches, it is 246 
of considerable interest to obtain a greater and more detailed level of knowledge 247 
regarding rate, extent and mechanisms of the processes by which anti-infectives 248 
permeate (actively or passively) across the envelope. Models which mimic the cell 249 
envelope and so enable provision of such information can thus help to facilitate 250 
the rational design of anti-infective agents, capable of overcoming intrinsic deliv-251 
ery difficulties/bacterial resistance mechanisms. Such models could additionally 252 
contribute useful information to early anti-infective drug discovery processes. The 253 
currently existing and employed models of the envelope structure, used in order to 254 
provide permeation and transport information, will be described in the following 255 
section. The needs which are unmet by these existing models will also be men-256 
tioned. 257 
3.1.1 Electrophysiology Studies 258 
 259 
Electrophysiological studies are applied to obtain information about the transport 260 
of anti-infectives through single porins. The principle of electrophysiology is 261 
based on the reconstitution of such channel forming proteins - mostly OmpF, as 262 
the main porin responsible for the passive OM permeation of many anti-infectives 263 
such as the ß-lactams and quinolones - into planar lipid bilayers (Figure 2A). Such 264 
bilayers mostly consist of phosphatidylcholine (PC), and are made for example by 265 
bursting porin-containing proteoliposomes across an aperture within a solid sup-266 
port (Kreir et al. 2008). An external voltage is then applied across the aperture-267 
spanning membrane, which causes an ion flux through the inserted porin channel. 268 
The strength of the resulting current allows for the provision of information re-269 
garding the channel structure and its functional properties in a variety of experi-270 
mental settings (e.g. ranges of salt concentration, pH). The technique is additional-271 
ly able to be automated (Mach et al. 2008a) and can be further optimized for 272 
example by applying the porin-containing supported lipid bilayer system into glass 273 
nanopipets (Gornall et al. 2011). In addition to providing information on porin 274 
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structure and function, anti-infective passage kinetics through the bilayer-275 
reconstituted porins can be studied by the use of high resolution ion-current fluc-276 
tuation analysis (Pages et al. 2008). In general, the permeation of anti-infective 277 
compounds through porins is detected by a decrease in current due to an occlusion 278 
of the porin channel by the permeating compound. Electrophysiological studies 279 
therefore facilitate determination of the direct translocation of charged molecules 280 
through porin channels. They additionally allow for evaluation of the interaction 281 
of anti-infectives with the constriction zone of porins (the narrowest part of the 282 
porin channel, which mediates the size-wise exclusion of molecule permeation 283 
across the OM) in particular. The relative affinity of different anti-infective com-284 
pounds for specific porins can also be elucidated using electrophysiological stud-285 
ies – for example, enrofloxacin has been shown to have the strongest recorded af-286 
finity for OmpF. Combining the information obtained from electrophysiology 287 
studies with molecular dynamic (MD) simulations enables the identification of the 288 
specific anti-infective pathway across porin channels (Nestorovich et al. 2002; 289 
Danelon et al. 2006; Mach et al. 2008b). This further contributes to understanding 290 
the occurrence of porin structure-related resistance mechanisms. Again taking the 291 
case of enrofloxacin, a relatively simple modification to the OmpF channel (a sin-292 
gle-point mutation in the constriction zone) has been shown by such a combina-293 
tion electrophysiology-MD approach to lead to a drastic decrease in anti-infective 294 
translocation (Mahendran et al. 2010). 295 
3.1.2 Liposome Based Assays 296 
 297 
Assays utilizing liposomes as artificial membrane models are also employed to in-298 
vestigate permeabilization effects of anti-infectives, as well as the extent of anti-299 
infective permeation into such model membranes. The existing liposome-based 300 
approaches can be basically differentiated into two major categories. On one hand 301 
the so-called liposome swelling assays or leakage studies must be mentioned. 302 
These approaches are based on uni- or multilamellar vesicles made of a single PL 303 
species (e.g. PC, PE) with or without incorporated porins (Nikaido and Rosenberg 304 
1983), PL mixtures, or PL-LPS (rough (without O-antigen) or smooth LPS (with 305 
O-antigen)) mixtures, utilized in an attempt to mimic the OM components. Poly-306 
mers or fluorescent dyes are further incorporated into the central aqueous com-307 
partment or within the bilayers of such liposomes. This provides for an indirect 308 
detection method for permeation of the analyzed anti-infective, by means of track-309 
ing changes in optical density (OD), or via fluorescence analysis. As an example 310 
of such a setup, the anti-infective of interest is mixed with polymer-containing 311 
liposome dispersions (which often also have inserted porins) under isosmotic con-312 
ditions. If the anti-infective is not able to penetrate into the vesicles, the measured 313 
OD will remain unaltered. If however the anti-infective compound is able to per-314 
meate into the liposomes, a swelling of the vesicles occurs due to an influx of wa-315 
ter, caused by the presence of an osmotic gradient as mediated by the permeating 316 
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anti-infective compound. Anti-infective permeation and liposome swelling can ul-317 
timately result in bursting of the liposomes, leading to a release of the incorpo-318 
rated polymer, which is then detectable as a decrease in OD (Figure 2B). Lipo-319 
some swelling or leakage assays also facilitate study of direct membrane 320 
disrupting effects of proteins (e.g. lamB or surfactant protein A) and antimicrobial 321 
peptides (AMPs, e.g. aurein 1.2) on artificial membrane systems (Luckey and 322 
Nikaido 1980; Kuzmenko et al. 2006; Fernandez et al. 2012; Fernandez et al. 323 
2013). Of considerable current interest with respect to such assays is the use of 324 
liposomes which imitate more closely Gram negative bacterial membrane compo-325 
sitions. In this respect, liposomes made of LPS or PL-LPS mixtures as a more re-326 
alistic OM mimic are also often used for swelling or leakage studies, or to investi-327 
gate PL-LPS interactions within the model membrane. Such studies could help to 328 
improve understanding of the OM organization or modulation of the OM during 329 
the development of resistance mechanisms (D'Errico et al. 2009; Kubiak et al. 330 
2011). 331 
 332 
On the other hand, liposomes can be used to study the accumulation and uptake of 333 
anti-infective compounds in liposomal membranes by direct analysis of anti-334 
infectives themselves. In this respect, anti-infectives of interest, which are either 335 
auto-fluorescent or fluorescently labeled, are incubated with liposomes. The rela-336 
tion between anti-infective structural characteristics/modifications and interaction 337 
with the artificial liposomal membrane can then be studied, as can anti-infective 338 
uptake into such model membranes. This is achieved by determining the accumu-339 
lation of anti-infectives within the lipid membrane or their uptake into the vesi-340 
cles, analyzed via nucleic magnetic resonance spectroscopy or fluorescence mi-341 
croscopy (Rodrigues et al. 2003; Ries et al. 2015).  342 
3.1.3 Langmuir Trough Based Approaches 343 
 344 
Mono- and/or bilayers prepared from PL and/or LPS in various combinations are 345 
also employed as models in anti-infective research. Such approaches facilitate in-346 
vestigation of the organization and interactions within artificial membrane systems 347 
and, with respect to permeation, study of the influence of antimicrobial proteins or 348 
peptides in particular on membrane integrity. In general, these experimental set-349 
ups were originally developed to study interactions within mammalian-mimicking 350 
membrane structures, or interaction of external entities with such structures. Imita-351 
tion of the double bilayer nature of the Gram negative bacterial envelope, as well 352 
as the OM, with particular emphasis being placed on its structural components and 353 
asymmetric nature, is however of considerable interest in the current application 354 
of such approaches. 355 
 356 
Preparation of lipid monolayers on the surface of water or buffer is achieved by 357 
using a Langmuir film balance or trough, whereas lipid bilayers are mostly pre-358 
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pared as supported lipid bilayers (SLBs) on silicon - less often mica or gold - sur-359 
faces as solid supports. SLBs in turn can be prepared from lipid vesicles which are 360 
fused onto the solid support, via Langmuir-Blodgett (LB) or a combination of LB 361 
and Langmuir-Schaefer (LS) deposition techniques (Peetla et al. 2009). An ad-362 
vancement of SLBs resulting in the production of more bacteriomimetic models is 363 
represented by the additional incorporation of floating lipid bilayers. Production of 364 
such a model involves combining three vertical LB depositions with one horizon-365 
tal LS deposition (Figure 2C), resulting in the formation of a lipid bilayer which 366 
floats at a distance of 2-3 nm from the supported lipid bilayer (Charitat et al. 1999; 367 
Fragneto et al. 2012). Langmuir-derived lipid bilayers are often prepared from PC 368 
or PC-PG mixtures (in order to mimic the negative charge of bacterial mem-369 
branes) and used to study the membrane insertion potential of AMPs, as well as 370 
their disordering and transmembrane pore forming abilities. Results show a higher 371 
affinity and disruptive effect on models composed of negatively charged PLs 372 
(Fernandez et al. 2012; Fernandez et al. 2013). Langmuir-produced monolayers 373 
made of PG with or without incorporated OmpF have also been used to investigate 374 
the interaction of antibacterial proteins such as colicins with the OM, as well as 375 
their pathway across the OM (Clifton et al. 2012). As mentioned above, many 376 
such Langmuir-based models additionally take the impact of LPS as the major 377 
OM structural component into account. In one instance, stable Langmuir mono-378 
layers were prepared at the air-liquid interface using rough strain LPS. Such a 379 
model provided valuable information about LPS structure at the air-liquid inter-380 
face, and therefore constitutes a further step to a more accurate model of the OM 381 
(Le Brun et al. 2013). In a further approach, a realistic mimic of the OM structure 382 
was prepared by combining a PC bilayer deposited via LB on a solid support (rep-383 
resenting the inner OM leaflet) with an overlying rough strain LPS bilayer (outer 384 
OM leaflet), introduced via LS deposition. This model successfully mimics the 385 
asymmetric nature of the OM, and was first employed to describe the molecular 386 
mechanisms of the well-known OM destabilization effect occurring as a result of 387 
the removal of divalent cations from surrounding media (Clifton et al. 2015). 388 
 389 
 390 
 391 
 392 
 393 
 394 
 395 
 396 
 397 
 398 
 399 
 400 
 401 
 402 
 403 
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Fig. 2. Schematic overview of in vitro approaches to produce bacterial membrane models, 417 
for the characterization of drug transport. (A) The experimental setup for electrophysiolo-418 
gy studies to investigate anti-infective transport through porins, incorporated in planar li-419 
pid bilayers (adapted from Modi et al. 2012 with permission from The Royal Society of 420 
Chemistry);(B) the principle of a liposome swelling assay, employed to assess permeabiliza-421 
tion processes mediated by anti-infective compounds (reprinted from Pages et al. 2008 by 422 
permission from Macmillan Publishers Ltd: [Nature Reviews Microbiology] Pages et al. 423 
2008, copyright 2008); (C) the Langmuir-based preparation procedure for preparing float-424 
ing lipid bilayers (from Fragneto et al. 2012, with kind permission from Springer Sci-425 
ence+Business Media) is additionally depicted . 426 
3.1.4 In Silico Methods 427 
 428 
Besides the so-far described in vitro models, in silico approaches are also utilized 429 
to investigate the impact and interaction of various lipid species within simulated 430 
bilayers (which in turn may have a bearing on anti-infective permeability). They 431 
are furthermore applied to inform the development of membrane models which 432 
more closely and accurately reflect the structure and components of the IM and 433 
OM. In silico approaches may also be employed to determine the affinity and/or 434 
translocation of anti-infectives with or across porin channels, as alluded to previ-435 
ously (see 3.1.1). They may additionally be used to screen compounds for anti-436 
infective activity based on quantitative structure-activity relationships (QSARs), 437 
defined via topological descriptors (numerical values correlating chemical proper-438 
ties with biological activity (Mayers 2009)) and physicochemical parameters. In 439 
one example, MD simulations have been used to mimic the IM – consisting of PE 440 
and PG in a 3:1 ratio, closely reflecting the in cellulo composition – in order to 441 
evaluate intra-bilayer PL interactions. Conducted simulations showed that interac-442 
tions between these specific PLs are mainly based on H-bond formation and chief-443 
ly occur between PE and PG, less often between only PE molecules and almost 444 
never between PG molecules alone. As a consequence, the presence of PG within 445 
the membrane leads to a decrease in PE headgroup protrusion and a reduced mo-446 
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tion along the artificial membrane; this results in an enhanced membrane stability, 447 
leading to a strengthening of the IM permeation barrier (Murzyn et al. 2005; Zhao 448 
et al. 2008). In silico studies which even more accurately reflect the PL composi-449 
tion of the IM have also been conducted. As a first step bilayers consisting of CL 450 
alone were simulated, to determine its biophysical role within membranes via 451 
evaluation of its charge-dependent lipid packing (Lemmin et al. 2013). Further, 452 
IM models which additionally include heterogeneous lipids, exhibiting different 453 
acyl chain lengths and cyclopropane rings, can be considered as yet further im-454 
provements towards an accurate IM mimic (Pandit and Klauda 2012).  455 
 456 
The OM has also been simulated in various in silico studies, starting with models 457 
consisting of LPS alone and followed by simulations using a combination of a PL 458 
inner leaflet and LPS outer leaflet to more accurately reflect the asymmetric OM 459 
structure. These models have largely been used to study properties such as interac-460 
tions between LPS molecules in the OM, the stabilization effect of divalent cati-461 
ons on the membrane structure (and resulting barrier properties), the effect of elec-462 
troporation on the barrier function of protein-free, asymmetric membrane 463 
structures and the impact of OM enzymes as well as proteins on membrane integ-464 
rity (Lins and Straatsma 2001; Wu et al. 2014; Piggot et al. 2011). Simulations of 465 
the OM as well as the IM have additionally been employed to study the interaction 466 
of AMPs with such artificial systems, highlighting the way in which AMPs are 467 
able to pass through and disrupt the bacterial envelope – firstly due to a self-468 
promoted uptake across the OM, and subsequently as a result of disruption of the 469 
IM via the formation of micelle-like aggregates (Berglund et al. 2015). MD simu-470 
lations have further been used to determine the molecular and rate-limiting inter-471 
actions occurring during anti-infective permeation through porins on an atomic 472 
scale. Such studies allow for a better understanding of the translocation pathway 473 
and estimated permeation time of anti-infective compounds, as well as the way in 474 
which modifications in the porin channel constriction zone can affect and reduce 475 
anti-infective permeation (Mach et al. 2008b; Mahendran et al. 2010; Singh et al. 476 
2012; Hajjar et al. 2010). In silico screening has furthermore been employed to de-477 
fine QSARs of anti-infectives by evaluating the impact of physicochemical prop-478 
erties such as lipophilicity and molecular weight on anti-infective activity (O'Shea 479 
and Moser 2008; Cronin et al. 2002). The definition of topological descriptors to-480 
gether with the performance of linear discriminant analysis further enable the at-481 
tainment of discriminant functions, which allow for differentiation between active 482 
and non-active anti-infectives. Such functions can subsequently be applied to 483 
screen compound libraries for new lead structures showing promising anti-484 
infective activity. (Murcia-Soler et al. 2003; Murcia-Soler et al. 2004). 485 
 486 
 487 
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3.1.5 In Cellulo Approaches 488 
 489 
In cellulo approaches which give information about permeability processes by fa-490 
cilitating the determination of intra-bacterial accumulated anti-infectives are of 491 
enormous interest, as such approaches of course constitute the most accurate rep-492 
resentation of the envelope structure. Within the scope of these approaches, a large 493 
number of bacteria are usually incubated with the anti-infective compound of in-494 
terest. This is followed by washing to remove remaining extracellular and/or ad-495 
herent compound, lysis of the bacterial cells and subsequent quantification of the 496 
amount of intracellular drug. LC-MS/MS methods are generally employed in or-497 
der to quantify what often proves to be a very low level of anti-infective com-498 
pound. Such quantification methods are also frequently applied to examine the 499 
permeation of various different anti-infectives tested on distinct bacterial strains 500 
(Cai et al. 2009; Davis et al. 2014). As such an approach is possibly error-prone 501 
due to the potential for inadequate removal of extracellular/adherent anti-infective, 502 
as well as the population-based rather than single-cell nature of the quantification 503 
process, approaches with direct single-cell resolution based on deep ultraviolet 504 
(DUV) fluorescence or the combination of a DUV fluorescence microscope with a 505 
synchrotron beamline have been employed. These approaches allow for quantify-506 
ing fluorescent or fluorescently-labeled compounds, and for example have been 507 
used to compare anti-infective uptake in wildtype and mutant/resistant bacterial 508 
strains (Pages et al. 2013; Kascakova et al. 2012). It must be mentioned here how-509 
ever that such an approach is still limited to an ‘inside/outside’ distinction of anti-510 
infective location, and determination of anti-infective permeation with any higher 511 
degree of spatial resolution remains extremely difficult. 512 
3.1.6 Shortcomings of Existing Models and Future Directions 513 
 514 
The current modeling approaches discussed in this section help to get a better un-515 
derstanding of permeation processes across various sub-structures of the Gram 516 
negative bacterial cell envelope. However, drawbacks and unmet needs can be 517 
mentioned for each of the above categories of models available to date. As a gen-518 
eral comment, the in vitro and in silico modeling approaches described here most-519 
ly focus on producing or simulating structures which approximate either the IM or 520 
OM, and not the cell envelope as a whole – or, in the small number of cases where 521 
the overall envelope structure is approximated, the resulting model is often tai-522 
lored to the examination of intra-membrane interactions or causes of membrane 523 
disruption. In addition, many such models consist of a phospholipid composition 524 
which deviates from that found in cellulo, and, while it has been mentioned that 525 
attempts are made in some cases to represent the asymmetric structure of the OM 526 
in models of this membrane component, many models still neglect to feature this 527 
important aspect. Furthermore, due to considerable difficulties associated with 528 
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scale and resolution, the vast majority of models to date allow for a qualitative 529 
prediction of anti-infective permeation and transport, rather than for quantification 530 
of such processes. In cellulo approaches where multiple planktonic cells rather 531 
than single cells are used have proven very useful in order to provide detailed and 532 
in some cases, quantitative insights into permeation processes; however, as men-533 
tioned, such methods generally rely on an average permeation within a bacterial 534 
population to draw conclusions regarding single cell permeation. Furthermore, 535 
current in cellulo approaches do not allow for evaluation of the specific extent of 536 
anti-infective permeation into the envelope structure. Hence, models which mimic 537 
the overall envelope in terms of their PL composition and structure, which are de-538 
signed to explicitly investigate and quantify transport and permeation processes, 539 
and which are able to discriminate between active and passive permeation of anti-540 
infective compounds and delivery systems in both a spatially- and kinetically- re-541 
solved manner are desperately needed.  542 
 543 
3.2 Improving Bacterial Bioavailability using Advanced Delivery 544 
Strategies  545 
In addition to employment and development of bacterial permeation models, a di-546 
rect research focus is also placed on anti-infective therapies themselves in an at-547 
tempt to overcome the cell envelope structure, achieve an increase in intra-548 
bacterial drug concentrations, and, in doing so, improve bioavailability in bacteria. 549 
In this respect, the search for new anti-infective drug candidates as well as the in-550 
vestigation of alternative approaches to antibiotic therapy continues, as presented 551 
and discussed in detail elsewhere. Additional strategies, such as the re-formulation 552 
of currently available anti-infectives with permeation-enhancing excipients or the 553 
application of advanced carrier systems, also represent promising research direc-554 
tions. Such strategies are particularly valuable in instances where bacterial bioa-555 
vailability issues cannot be directly resolved by the introduction of new molecules, 556 
or through modification of existing anti-infective structures using medicinal chem-557 
istry approaches. As such, a number of currently investigated advanced formula-558 
tion strategies are presented below.  559 
3.2.1 Efflux Pump Inhibitors 560 
 561 
As mentioned in section 2.1, efflux in wild-type as well as drug resistant Gram 562 
negative bacteria is mainly mediated by the RND superfamily of efflux transport-563 
ers. The use of formulations incorporating efflux pump inhibitors (EPIs) which are 564 
able to interact with such pumps, decreasing anti-infective efflux and subsequently 565 
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leading to higher intracellular drug levels, therefore represents a useful strategy to 566 
restore anti-infective potency. The inhibition of pumps as mediated by EPIs can be 567 
described as occurring by two major modes of action. One can be classified as 568 
biological, in which EPIs act to decrease the expression of the pumps themselves 569 
by inhibiting transcription or translation via antisense oligonucleotides. A pharma-570 
cological mechanism represents the second mode of action, in which EPIs operate 571 
through direct interaction with the pump affinity site, acting for example to col-572 
lapse the efflux energy or to competitively or non-competitively inhibit the efflux 573 
process (Van Bambeke et al. 2010). EPIs can be further differentiated into inhibi-574 
tors with a narrow spectrum of activity, being used as diagnostic tools to detect ac-575 
tive efflux, or inhibitors with a broad spectrum of action, which could be poten-576 
tially useful in clinical settings. The further ability of EPIs to restore the activity of 577 
simultaneously applied anti-infectives (being visible for example in a decrease of 578 
minimum inhibitory concentration (MIC)) makes them an even more promising 579 
approach as a means to increase anti-infective bacterial bioavailability. Examples 580 
of known EPIs include analogues or lead structures of tetracyclines or fluoroquin-581 
olones, arylpiperidine and phenothiazine derivatives as well as peptidomimetics 582 
(Pages and Amaral 2009). Peptidomimetics with phenylalanine arginyl ß-583 
naphthylamine (PAßN) as lead compound represent the first efflux inhibiting 584 
group which showed an effective blocking of fluoroquinolone efflux in a RND 585 
over-expressing strain of Pseudomonas aeruginosa (Renau et al. 2002). Currently, 586 
EPIs are used primarily as in vitro screening tools; their potential use in the clinic 587 
is still under investigation due to the existence of several challenging factors. The 588 
primary obstacle to the use of EPIs in a clinical setting is that of toxicity - most of 589 
the known EPIs to date need to be used in high concentrations, which may lead to 590 
possible toxic effects. Their use in combination with anti-infectives also demands 591 
the absence of interactions between the EPI and the anti-infective compound, as 592 
well as comparability in their pharmacokinetic profiles.  593 
3.2.2 Antimicrobial Peptides 594 
 595 
The use of the previously mentioned AMPs, either alone or especially in synergis-596 
tic combinations with conventional anti-infectives, represents a further strategy to 597 
overcome anti-infective bioavailability problems by enhancing their transport 598 
across the bacterial cell envelope. AMPs can be further used as stimuli for the in-599 
nate immune system, or as endotoxin-neutralizing agents (Gordon et al. 2005). 600 
AMPs in themselves are generally small cationic peptides which can be derived 601 
from humans, bacteria, or even viruses (Yount and Yeaman 2004). Their mode of 602 
action as bioavailability-potentiating agents is primarily based on the initiation of 603 
bacterial membrane perturbation, an effect mainly mediated by electrostatic inter-604 
actions between the positively charged peptide and the negatively charged LPS of 605 
the OM. Such interactions lead to a destabilization of the OM by displacing pre-606 
sent divalent cations, which facilitates penetration of AMPs and any other associ-607 
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ated compounds through the OM structure. Following this self-promoted uptake 608 
through the OM, the further association of AMPs with the outer leaflet of the IM 609 
followed by the formation of micelle-like aggregates finally leads to a rupture of 610 
the bacterial envelope. This allows either for bacterial killing, or for an even fur-611 
ther enhanced uptake of the simultaneously administered anti-infective. A non-612 
destructive action of AMPs, facilitated by binding to DNA or RNA, is also further 613 
described (Hancock 1997; Hancock and Chapple 1999). Several studies report the 614 
potentiating effect of AMP–anti-infective combinations, resulting in an increased 615 
anti-infective activity even in hard to treat bacterial strains and biofilm forming 616 
species. In this respect, the synergistic effect of AMPs together with a wide range 617 
of anti-infectives with different modes of action could be demonstrated by the ef-618 
fective treatment of Clostridium difficile (Nuding et al. 2014). Furthermore, com-619 
binations of AMPs with anti-infectives have shown to result in an increased activi-620 
ty against the biofilm formation of Methicillin Resistant Staphylococcus aureus 621 
(MRSA), and have demonstrated a successful inhibition of Pseudomonas fluo-622 
rescens (Mataraci and Dosler 2012; Naghmouchi et al. 2012). Hence, AMPs rep-623 
resent a promising approach to improve anti-infective bioavailability in Gram 624 
negative as well as Gram positive bacteria, as well as in particularly problematic 625 
bacterial infections involving biofilm formation. Several clinical trials, especially 626 
for topical application of AMPs to human subjects, are ongoing, but are associated 627 
with several challenges. In addition to the potential for toxic effects which could 628 
for example result from non-specific membrane disruption, the fast degradation 629 
and short half-life of AMPs constitute the main obstacles to generalized use (Park 630 
et al. 2011). The incorporation of AMPs into particulate carrier systems could po-631 
tentially help to reduce or overcome these difficulties – such approaches are fur-632 
ther discussed below. 633 
3.2.3 Nanoparticulate Drug Carriers (“Nanopharmaceuticals”)  634 
 635 
Anti-infectives as free drugs may show low water-solubility, unfavorable pharma-636 
cokinetics, side effects or stability problems (Xiong et al. 2014) – all factors which 637 
intrinsically create problems for penetration into and effective action within bacte-638 
ria. The incorporation of anti-infectives into carrier systems, such as liposomes, 639 
polymeric nanoparticles, solid lipid nanoparticles (SLNs) or dendrimers may help 640 
to reduce the impact of such characteristics, and as such presents several ad-641 
vantages compared to the use of free anti-infectives. In light of their typical size 642 
range, these carriers are nowadays also regarded as nanomaterials or nanoparti-643 
cles, and with respect to their specific application also referred to as nanomedi-644 
cines or nanopharmaceuticals.   645 
 646 
The incorporation of anti-infectives into nanoparticulate carrier systems may al-647 
low for a high drug loading in some cases, facilitating an increase in effective drug 648 
solubility; a masking of undesirable drug effects; a tailoring of anti-infective 649 
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pharmacokinetics; or a directly increased permeability. Modifications for example 650 
to the particle surface may allow for further improvements, such as a targeted de-651 
livery. One of the first examples of a nanoparticulate anti-infective formulation 652 
which was granted access to the market is a liposomal formulation of amphoteri-653 
cin B – this formulation remains widely used in clinical settings due to the exhibi-654 
tion of many of the above mentioned advantages (Walsh et al. 1998). Polymeric 655 
nanoparticles are also extensively investigated as carriers for anti-infective drugs 656 
in several labs around the globe. The protective function of particulate carriers and 657 
the possibility for co-loading is also a considerable advantage with respect to de-658 
livery of readily-degraded compounds like AMPs. The possibility to incorporate 659 
more than one anti-infective compound into particulate carriers, or to combine an-660 
ti-infective loaded carriers with particles of known antimicrobial substances like 661 
gold or silver, constitutes a further advantage to the use of such delivery systems 662 
(Huh and Kwon 2011). Significant progress in the development of nanotechnolo-663 
gy-based approaches specifically to treat bacterial infections has been made in re-664 
cent years, leading to the existence of several sophisticated carrier systems. For 665 
example, Trojan horse systems made of nanoparticles tagged with folic acid have 666 
been shown to mediate an increased activity of the incorporated anti-infective 667 
vancomycin in resistant Staphylococcus aureus (Chakraborty et al. 2012). The 668 
linkage of penicillin G to surface functionalized silica nanoparticles has also 669 
shown a restored anti-infective activity even in formerly resistant MRSA (Wang et 670 
al. 2014).  671 
 672 
Infection-activated delivery systems are another promising approach, being for 673 
example composed of chitosan-modified gold nanoparticles which are attached to 674 
liposomes or polymeric triple-layered nanogels. Substances like toxins or enzymes 675 
which are present in the local environment of a bacterial infection work as a trig-676 
ger for release of carrier-incorporated anti-infective, allowing for the reduction of 677 
potential side effects resulting from systemic anti-infective administration as well 678 
as the achievement of high local drug concentrations at the site of infection 679 
(Pornpattananangkul et al. 2011; Xiong et al. 2012). Anionic liposomes have also 680 
been successfully used to incorporate and deliver plasmid DNA and antisense oli-681 
gonucleotides into inner bacterial compartments in order to inhibit gene expres-682 
sion in resistant strains (Meng et al. 2009; Fillion et al. 2001). Recently, an SLN-683 
based formulation was successfully used to incorporate and deliver high amounts 684 
of a novel quorum sensing inhibitor (QSI), which act as anti-virulence factors by 685 
interfering with bacterial cell-cell communication via action on intracellular tar-686 
gets (Miller and Bassler 2001). SLNs with incorporated QSI showed a prolonged 687 
release, mucus penetrating ability and an effective delivery to the pulmonary re-688 
gion, as well as an enhanced anti-virulence activity against Pseudomonas aeru-689 
ginosa as compared to the compound alone (Nafee et al. 2014). As these examples 690 
illustrate, innovative delivery strategies (along with the search for and optimiza-691 
tion of novel anti-infective targets and compounds) offer the potential for over-692 
coming bacterial absorption problems.  693 
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3.2.4  Evaluation of Current Status and Future Directions 694 
 695 
The combination of EPIs and AMPs with conventional or even new anti-infectives 696 
may result in a reduction of undesirable intrinsic anti-infective properties as well 697 
as an increased bacterial permeation, leading to higher intracellular drug levels 698 
and so an enhanced bacterial bioavailability. Furthermore, carrier systems are able 699 
to provide a means of circumventing compound related difficulties, such as unfa-700 
vorable pharmacokinetics, and to achieve high intracellular drug levels. In this 701 
manner such advanced formulation strategies may act to increase the bioavailabil-702 
ity of anti-infectives, and for this reason continue to be employed and developed. 703 
The treatment of intracellular infections as well as the specific development of 704 
permeability enhancing carriers constitutes an important direction of future appli-705 
cations.   706 
4. Conclusion and Outlook 707 
This paper has aimed to give an overview of current difficulties in the treatment of 708 
infectious diseases, in particular those caused by Gram negative bacteria. In this 709 
respect, the significant bioavailability problems of anti-infective compounds - de-710 
fined as an inadequate delivery to their (mainly intra-bacterial) sites of action - 711 
largely stem from the complex nature of the cell envelope and its formidable bar-712 
rier function. This barrier function may be even further enhanced by the evolution 713 
of resistance mechanisms. Numerous models - in vitro, in silico as well as in cellu-714 
lo in nature - may be used in order to increase understanding of permeation pro-715 
cesses into or across the envelope, as well as to enable evaluation of how the cell 716 
envelope in its entirety or as its individual sub-structures acts as a permeation lim-717 
iting factor. However, a paucity of quantitative approaches which accurately mim-718 
ic the overall envelope structure has to be mentioned, meaning that obtained in-719 
formation may lack comprehensiveness. Therefore, new permeation models which 720 
more accurately represent the various structural components of the Gram negative 721 
bacterial cell envelope, and which are further able to provide quantitative, kinet-722 
ically- and spatially-resolved permeation data are desperately needed. Such mod-723 
els would also ideally allow for discrimination between active and passive 724 
transport processes, and would be applicable as high throughput screening meth-725 
ods in early drug discovery. With respect to anti-infective compounds themselves, 726 
the combination of EPIs or AMPs with conventional anti-infectives presents a 727 
promising strategy in overcoming bacterial bioavailability problems, enabling the 728 
restoration of anti-infective activity even in resistant strains. Particulate delivery 729 
systems may similarly facilitate an increase in anti-infective bioavailability, by 730 
acting to overcome drawbacks related to the free drug itself; such carrier systems 731 
may additionally facilitate a targeted delivery of anti-infectives. Anti-infective 732 
formulations which are designed to particularly increase the permeation or 733 
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transport of anti-infectives into or across the bacterial cell envelope, or to treat 734 
particularly problematic bacteria (such as those which reside within mammalian 735 
cells) are still urgently needed however, and would constitute a further significant 736 
improvement in anti-infective therapy. 737 
 738 
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